Lantheus Holdings (LNTH) Asset Writedowns and Impairment (2014 - 2026)
Lantheus Holdings (LNTH) posted quarterly Asset Writedowns and Impairment of $1.5 million for Q1 2026, up 211.54% year-over-year from $493358.0 in Q1 2025, and up 330.43% quarter-over-quarter from -$667000.0 in Q4 2025.
Lantheus Holdings (LNTH) Asset Writedowns and Impairment (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has reported Asset Writedowns and Impairment for 13 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Asset Writedowns and Impairment rose 211.54% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $5.1 million (up 223.75% YoY), while the FY2025 annual figure was $2.2 million, changed N/A from the prior year.
- Asset Writedowns and Impairment improved to $1.5 million in Q1 2026 per LNTH's latest filing, from -$667000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $132.1 million in Q1 2023 and bottomed at -$1.4 million in Q1 2025.
- Historically, Asset Writedowns and Impairment has averaged $12.4 million across 5 years, with a median of $1.7 million in 2025.
- Annual changes were most pronounced in 2022 — Asset Writedowns and Impairment surged 3680.42% — and 2025, when it tumbled 149.98%.
- Lantheus Holdings' Asset Writedowns and Impairment stood at $7.1 million in 2022, then retreated by 16.05% to $6.0 million in 2023, then plunged by 112.3% to -$738000.0 in 2024, then increased by 9.62% to -$667000.0 in 2025, then surged by 330.43% to $1.5 million in 2026.
- Business Quant data shows LNTH's Asset Writedowns and Impairment at $1.5 million in Q1 2026, -$667000.0 in Q4 2025, and $1.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Lantheus Holdings | 6.52 Bn | 5.93 Bn | 241.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 454,000.00 |
| Jun 30, 2026 | 454,000.00 |
| Mar 31, 2026 | 1.54 Mn |
| Mar 31, 2026 | 1.54 Mn |
| Dec 31, 2025 | -667,000.00 |
| Dec 31, 2025 | -667,000.00 |
| Sep 30, 2025 | 1.93 Mn |
| Sep 30, 2025 | 1.93 Mn |
| Jun 30, 2025 | 2.31 Mn |
| Jun 30, 2025 | 2.31 Mn |
| Mar 31, 2025 | -1.38 Mn |
| Mar 31, 2025 | -1.38 Mn |
| Dec 31, 2024 | -738,000.00 |
| Dec 31, 2024 | -738,000.00 |
| Sep 30, 2024 | -1.19 Mn |
| Sep 30, 2024 | -1.19 Mn |
| Jun 30, 2024 | -832,000.00 |
| Jun 30, 2024 | -832,000.00 |
| Mar 31, 2024 | 2.76 Mn |
| Mar 31, 2024 | 2.76 Mn |